<sup>18</sup>F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展

宋少莉; 黄钢

¹⁸F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展

宋少莉¹,
黄钢²

1. 200127 上海, 上海交通大学医学院附属仁济医院核医学科PET-CT中心;
2. 200127 上海, 上海交通大学临床核医学研究所
中图分类号: R817.4

The development of monitoring chemotherapy and radiotherapy of solid tumor by ¹⁸F-fluorodeoxyglucose PET

SONG Shao-Li¹,
HUANG Gang²

1. Department of PET-CT Center, School of Medicine, Shanghai JiaoTong University Shanghai. 200127, China;
2. Department of Nuclear Medicine, RenJi Hospital, School of Medicine, ShangHai JiaoTong University, Shanghai 200127, China
CLC number: R817.4

摘要: 利用¹⁸F-氟脱氧葡萄糖(¹⁸F-FDG)PET监测肿瘤放疗或化疗的疗效以及区分残余或复发病灶已广泛用于临床.¹⁸F-FDG PET定量分析肿瘤在治疗开始时的变化可以预测肿瘤对治疗的反应性及患者的预后,并可根据肿瘤的反应性调整治疗方案.利用¹⁸F-FDG PET早期预测肿瘤对放、化疗的反应性,在个体化治疗方案的制定、减少无效治疗所带来的副作用等方面有着巨大的潜能.
- 体层摄影术,发射型计算机 /
- 氟脱氧葡萄糖F18 /
- 肿瘤 /
- 药物疗法 /
- 放射疗法 /
- 预后
Abstract: ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET imaging monitoring tumor response in patients undergoing ehemo-and radiotherapy and differentiation residual or recurrent viable tumor and therapy-induced fibrosis or scar tissue has been documented for various solid tumors. Furthermore, there are now several reporis suggesting that quantitative assessment of therapy-induced changes in tumor ¹⁸F-FDG uptake may allow prediction of tumor response and patient outcome very early in the course of therapy. In nonresponding patients, trcatnlent may be adjusted according to the individual chemo-and radiosensitivity of the tumor tissue. Early prediction of tumor response to ehenlotherapy and radiotherapy by ¹⁸F-FDG PET has enormous potential to "personalize" treatment and to reduce the side-effects and costs of ineffective therapy.
- Tomograpy,emission-computed /
- Fluorodeoxyglucose F18 /
- Neoplasms /
- Durg therapy /
- Radiotherapy /
- Prognosis
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92(3):205-216.
[2]	Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk:an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 2002, 20(3):776-790.
[3]	Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction chemotherapy in locally advanced esophageal cancer. Ann Oncol, 2002, 13(3):361-368.
[4]	Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg, 2004, 78(4):1152-1160.
[5]	MacManus MP, Hicks R J, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol, 2003, 21(7):1285-1292.
[6]	Hellwig D, Graeter TP, Ukena D, et al. Value of F-18 fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg, 2004, 128(6):892-899.
[7]	Pottgen C, Levegrun S, Theegarten D, et al. Value of ¹⁸F-fluoro-2-de-oxy-D-glucose positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic re-sponse and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res, 2006, 12(1):97-106.
[8]	Kunkel M, Forster GJ, Reichert TE, et al. Radiation response non-invasively imaged by[¹⁸F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol, 2003, 39(2):170-177.
[9]	Grigsby PW, Siegel BA, Dehdashti F, et al. Posttherapy[¹⁸F]fluorodeoxyglucose positron emission tomography in carcinoma of the cervix:response and outcome. J Clin Oncol, 2004, 22(11):2167-2171.
[10]	Schuetze SM. Rubln BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer, 2005, 103(2):339-348.
[11]	Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma:response evaluation by positron emission tomography. Ann Surg, 2001,233(3):300-309.
[12]	Downey RJ, Akhurst T, Ilson D, et al. Whole body ¹⁸FDG-PET and the response of esophageal cancer to induction therapy:results of a prospective trial. J Clin Oncol, 2003, 21(3):428-432.
[13]	Weber WA, Ott K, Beckcr K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol, 2001, 19(12):3058-3065.
[14]	Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol, 2004, 22(5):900-908.
[15]	Ott K, Fink U, Becket K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging:results of a prospeetive trial. J Clin Oncol, 2003, 21(24):4604-4610.
[16]	Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment:prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck, 2002, 24(2):127-135.
[17]	Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol, 2005, 23(30):7445-7453.
[18]	Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-smallcell lung cancer:prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol, 2003, 21(14):2651-2657.
[19]	Hoekstra C J, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using[¹⁸F]-2-fluoro-2-deoxy-D-glucose positronemission tomography in patients with locally advanced nonsmallcell lung cancer. J Clin Oncol, 2005, 23(33):8362-8370.
[20]	Schiller JH, Harrington D, Belanl CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2):92-98.
[21]	Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using[¹⁸F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol, 2000, 18(8):1676-1688.
[22]	Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using[¹⁸F]fluorodeoxyglueose for monitoring primary chemotherapy in breast cancer. J Clin Oncol, 2000, 18(8):1689-1695.
[23]	Hicks RJ, Mac Manus MP, Matthews JP, et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer:inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys, 2004, 60(2):412-418.

[1]	吕慧清 , 张中民 , 吕仲虹 . ¹⁸F-氟代脱氧葡萄糖PET在恶性肿瘤适形放射治疗中的价值. 国际放射医学核医学杂志, 2006, 30(6): 335-337.
[2]	刘文静 , 赵新明 , 吴冯春 . ¹⁸F-FDG PET/CT对化疗中期弥漫性大B细胞淋巴瘤患者预后判断的价值. 国际放射医学核医学杂志, 2022, 46(5): 261-269. doi: 10.3760/cma.j.cn121381-202104017-00182
[3]	邢岩 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发. 国际放射医学核医学杂志, 2007, 31(6): 341-344.
[4]	叶慧 , 莫逸 , 谢爱民 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
[5]	张玉娜 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET-CT在头颈部肿瘤临床诊治中的价值. 国际放射医学核医学杂志, 2007, 31(6): 359-362.
[6]	陈跃 . 颅内肿瘤放射治疗后¹⁸F-氟代脱氧葡萄糖PET的临床意义. 国际放射医学核医学杂志, 2006, 30(2): 97-99.
[7]	王月英 , 吴红英 , 李德冠 , 王小春 , 宋娜玲 , 路璐 , 张俊伶 , 孟爱民 . 小鼠不同肿瘤模型对放化疗敏感性的研究. 国际放射医学核医学杂志, 2012, 36(5): 289-292. doi: 10.3760/cma.j.issn.1673-4114.2012.05.006
[8]	夏伟 , 罗全勇 , 袁志斌 . PET-CT在肿瘤放射治疗中的应用. 国际放射医学核医学杂志, 2006, 30(6): 331-335.
[9]	郭仲秋 , 刘启志 , 潘桂霞 , 张卫 , 李潇 , 王涛 , 崔斌 , 左长京 , 程超 . ¹⁸F-FDG PET/CT相关参数预测结直肠癌切除术预后的价值. 国际放射医学核医学杂志, 2019, 43(4): 295-302. doi: 10.3760/cma.j.issn.1673-4114.2019.04.001
[10]	李剑明 , 李亚明 . 棕色脂肪组织与¹⁸F-氟脱氧葡萄糖PET. 国际放射医学核医学杂志, 2007, 31(4): 205-207,231.

点击查看大图

计量

文章访问数: 1384
HTML全文浏览量: 79
PDF下载量: 2

¹⁸F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展

The development of monitoring chemotherapy and radiotherapy of solid tumor by ¹⁸F-fluorodeoxyglucose PET

计量

¹⁸F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展

English Abstract

The development of monitoring chemotherapy and radiotherapy of solid tumor by ¹⁸F-fluorodeoxyglucose PET

全文HTML

目录

18F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展

The development of monitoring chemotherapy and radiotherapy of solid tumor by 18F-fluorodeoxyglucose PET

计量

出版历程

18F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展

English Abstract

The development of monitoring chemotherapy and radiotherapy of solid tumor by 18F-fluorodeoxyglucose PET

全文HTML

目录

¹⁸F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展

The development of monitoring chemotherapy and radiotherapy of solid tumor by ¹⁸F-fluorodeoxyglucose PET

¹⁸F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展

The development of monitoring chemotherapy and radiotherapy of solid tumor by ¹⁸F-fluorodeoxyglucose PET